MA42532B1 - Constructions d'anticorps pour flt3 et cd3 - Google Patents

Constructions d'anticorps pour flt3 et cd3

Info

Publication number
MA42532B1
MA42532B1 MA42532A MA42532A MA42532B1 MA 42532 B1 MA42532 B1 MA 42532B1 MA 42532 A MA42532 A MA 42532A MA 42532 A MA42532 A MA 42532A MA 42532 B1 MA42532 B1 MA 42532B1
Authority
MA
Morocco
Prior art keywords
antibody construct
flt3
relates
polynucleotide
antibody constructs
Prior art date
Application number
MA42532A
Other languages
English (en)
Other versions
MA42532A (fr
Inventor
Peter Kufer
Tobias Raum
Patrick Hoffmann
Jochen Pendzialek
Claudia Bluemel
Christoph Dahlhoff
Elisabeth Nahrwold
Franziska Bott
Markus Muenz
Johannes Brozy
Matthias Friedrich
Benno Rattel
Pamela Bogner
Andreas Wolf
Cornelius Pompe
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Priority claimed from PCT/EP2016/068319 external-priority patent/WO2017021362A1/fr
Publication of MA42532A publication Critical patent/MA42532A/fr
Publication of MA42532B1 publication Critical patent/MA42532B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une construction d'anticorps bispécifique comprenant un premier domaine de liaison qui se lie à la flt3 humaine sur la surface d'une cellule cible et un second domaine qui se lie au cd3 humain sur la surface d'un lymphocyte t. L'invention concerne également un polynucléotide codant pour cette construction d'anticorps, un vecteur comprenant ledit polynucléotide et une cellule hôte transformée ou transfectée avec ledit polynucléotide ou ledit vecteur. Par ailleurs, l'invention concerne un procédé de production de la construction d'anticorps susmentionnée, une utilisation médicale de cette construction d'anticorps et une trousse comprenant ladite construction d'anticorps.
MA42532A 2015-07-31 2016-08-01 Constructions d'anticorps pour flt3 et cd3 MA42532B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199944P 2015-07-31 2015-07-31
PCT/EP2016/068319 WO2017021362A1 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps pour flt3 et cd3

Publications (2)

Publication Number Publication Date
MA42532A MA42532A (fr) 2018-06-06
MA42532B1 true MA42532B1 (fr) 2023-05-31

Family

ID=60245275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42532A MA42532B1 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps pour flt3 et cd3

Country Status (2)

Country Link
AR (1) AR105561A1 (fr)
MA (1) MA42532B1 (fr)

Also Published As

Publication number Publication date
MA42532A (fr) 2018-06-06
AR105561A1 (es) 2017-10-18

Similar Documents

Publication Publication Date Title
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
CY1126145T1 (el) Κατασκευασματα αντισωματων για flt3 και cd3
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
WO2018056821A8 (fr) Molécules de liaison qui modulent une activité biologique exprimée par une cellule
JOP20210022A1 (ar) بنيات جسم مضاد لـ cldn18.2وcd3
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
EA201890383A1 (ru) Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3)
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201890390A8 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
JO3714B1 (ar) تركيبات الجسم المضاد لـ cd70 و cd3
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018005389A (es) Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EA201892440A1 (ru) Антитела к tl1a и их применения
MX2020003503A (es) Proteinas de union al antigeno del receptor de oncostatina m.
MA39342B2 (fr) Anticorps il -21
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека